UK Markets close in 4 hrs 57 mins

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.7300+0.1800 (+7.06%)
At close: 04:00PM EDT
2.7300 0.00 (0.00%)
After hours: 07:37PM EDT

Compass Therapeutics, Inc.

80 Guest Street
Suite 601
Boston, MA 02135
United States
617 500 8099
https://www.compasstherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees24

Key executives

NameTitlePayExercisedYear born
Dr. Thomas J. Schuetz M.D., Ph.D.Co-Founder, CEO & Director454kN/A1961
Dr. Vered Bisker-Leib MBA, Ph.D.Pres & COO720kN/A1971
Dr. Susan Kalled Ph.D.Chief Scientific Officer445.5kN/A1961
Mr. Neil L. Lerner CPAVP of Fin.N/AN/A1967
Mr. Jonathan Anderman J.D.VP, Head of Legal & Corp. Sec.N/AN/AN/A
Anna GiffordCommunications Mang.N/AN/AN/A
Dr. Peter F. Moesta Ph.D.Interim Head of CMCN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corporate governance

Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.